Monkeypox renamed "mpox" in an effort to combat stigma

As of November 29, 2022, the World Health Organization (WHO) has announced that the monkeypox virus will now be referred to as “mpox” in an effort to reduce the stigmatization of this condition.

 

Image Credit: Berkay Ataseven / Shutterstock.com

“Mpox”

Since the start of the current mpox outbreak in numerous non-endemic regions throughout the world, racist and stigmatizing language and have been widely spread on social media platforms. Following the increasing number of concerns raised by many individuals and countries over this issue, the WHO, under the International Classification of Diseases (CID) and the WHO Family of International Health Related Classifications, recommended the adoption of “mpox” to replace the use of “monkeypox” in WHO communications.

Removing ‘monkey’ removes the stigma that monkeypox comes with and deals with the possible misinformation.”

The current status of the mpox outbreak

Over 81,000 cases of mpox virus infection have been reported worldwide in 110 different locations, 103 of which are non-endemic areas.

The mpox virus, an Orthopoxvirus with manifestations similar to smallpox infection, usually is endemic to central and west African countries. However, in April of this year, several new mpox cases were reported in other areas of the world, many of which were documented in men who have sex with men (MSM).

Mpox symptoms and transmission

Symptoms will begin to develop about three weeks after being infected with the mpox virus. The most common mpox infection symptom is a rash located on or near the genitals and anus and other areas of the body, including the hands, feet, chest, face, or mouth. The pimple/blister-like appearance of the mpox rash will eventually scab before healing.

In addition to a rash, mpox infection may cause fever, chills, swollen lymph nodes, fatigue, muscle aches, headache, and respiratory symptoms, including a cough, sore throat, or nasal congestion.

The most common way mpox is transmitted is through skin-to-skin contact with an infected individual, such as sexual intercourse, hugging, kissing, or prolonged face contact. In addition to this transmission route, the mpox virus can also be transmitted following contact with contaminated objects, fabrics, and surfaces previously used by an infected individual.

Extracellular, brick-shaped mpox virions (colorized pink). Backlighting shows the surface membranes of the virions and the outlines of nucleocapsids. Credit: NIAID.

Extracellular, brick-shaped mpox virions (colorized pink). Backlighting shows the surface membranes of the virions and the outlines of nucleocapsids. Credit: NIAID.

Vaccines

In the United States, the JYNNEOS and ACAM2000 vaccines have been approved to prevent the spread of the mpox virus due to the structural similarities between the mpox and smallpox viruses. Individuals previously exposed to a mpox-infected individual will likely be exposed to mpox in the future or are immunocompromised and are advised to receive either vaccine to prevent infection.  

Treatments

Importantly, no specific mpox antiviral agents have been approved for use; however, antiviral agents initially developed for treating smallpox infection may also be effective in treating mpox infection. Only those currently experiencing severe forms of mpox infection or are considered high risk for severe disease are eligible to receive these treatments.

Tecovirimat, for example, is considered the first line of therapy for treating at-risk patients with mpox infection. This antiviral medication is typically administered as a prophylactic measure to exposed individuals with severe immunodeficiency in T-cell function and would otherwise not be eligible to receive smallpox/mpox vaccination.

Brincidofovir, otherwise known as Tembex, is another smallpox drug available for treating mpox infections in adults. Only mpox-positive individuals experiencing severe disease or are at risk of severe infection can receive this drug.

In addition to these agents, vaccinia immune globulin intravenous (VIGIV) and cidofovir are other therapeutic modalities that may be employed in treating mpox infection.

Sources:
Benedette Cuffari

Written by

Benedette Cuffari

After completing her Bachelor of Science in Toxicology with two minors in Spanish and Chemistry in 2016, Benedette continued her studies to complete her Master of Science in Toxicology in May of 2018. During graduate school, Benedette investigated the dermatotoxicity of mechlorethamine and bendamustine; two nitrogen mustard alkylating agents that are used in anticancer therapy.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cuffari, Benedette. (2022, November 29). Monkeypox renamed "mpox" in an effort to combat stigma. News-Medical. Retrieved on February 08, 2023 from https://www.news-medical.net/news/20221129/Monkeypox-renamed-mpox-in-an-effort-to-combat-stigma.aspx.

  • MLA

    Cuffari, Benedette. "Monkeypox renamed "mpox" in an effort to combat stigma". News-Medical. 08 February 2023. <https://www.news-medical.net/news/20221129/Monkeypox-renamed-mpox-in-an-effort-to-combat-stigma.aspx>.

  • Chicago

    Cuffari, Benedette. "Monkeypox renamed "mpox" in an effort to combat stigma". News-Medical. https://www.news-medical.net/news/20221129/Monkeypox-renamed-mpox-in-an-effort-to-combat-stigma.aspx. (accessed February 08, 2023).

  • Harvard

    Cuffari, Benedette. 2022. Monkeypox renamed "mpox" in an effort to combat stigma. News-Medical, viewed 08 February 2023, https://www.news-medical.net/news/20221129/Monkeypox-renamed-mpox-in-an-effort-to-combat-stigma.aspx.

Comments

  1. Huh
    Richard Bruler Richard Bruler Canada says:

    What stigma? Who's offended now?

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Reports of Mpox disease following recent vaccination